Key result
The CRT-SCORE demonstrated good discriminative ability for predicting 1- and 5-year survival after cardiac resynchronization therapy (AUC 0.773 at 1 year and 0.748 at 5 years).
Why the study?
Does the CRT-SCORE accurately predict 1- and 5-year survival rates in patients with LVEF ≤35% undergoing cardiac resynchronization therapy?
Cohort (n=1,053)
Does the CRT-SCORE accurately predict 1- and 5-year survival rates in patients with LVEF ≤35% undergoing cardiac resynchronization therapy?
Effect estimate: AUC 0.773 at 1 year and 0.748 at 5 years
The CRT-SCORE is a multiparametric tool that accurately predicts 1- and 5-year survival after CRT implantation, which may assist clinicians in patient counseling and shared decision-making.
May aid counseling in CRT candidates; leaves open prospective validation before routine use.
Individualized estimation of prognosis after cardiac resynchronization therapy (CRT) remains challenging. Our aim was to develop a multiparametric prognostic risk score (CRT-SCORE) that could be used for patient-specific clinical shared decision making about CRT implantation. The CRT-SCORE was derived from an ongoing CRT registry, including 1,053 consecutive patients (age 67 ± 10 years, 76% male). Using preimplantation variables, 100 multiple imputed datasets were generated for model calibration. Based on multivariate Cox regression models, cross-validated linear prognostic scores were calculated, as well as survival fractions at 1 and 5 years. Specifically, the CRT-SCORE was calculated using atrioventricular junction ablation, age, gender, etiology, New York Heart Association class, diabetes, hemoglobin level, renal function, left bundle branch block, QRS duration, atrial fibrillation, left ventricular systolic and diastolic functions, and mitral regurgitation, and showed a good discriminative ability (areas under the curve 0.773 at 1 year and 0.748 at 5 years). During the long-term follow-up (median 60 months, interquartile range 31 to 85), all-cause mortality was observed in 494 (47%) patients. Based on the distribution of the CRT-SCORE, lower- and higher-risk patient groups were identified. Estimated mean survival rates of 98% at 1 year and 92% at 5 years were observed in the lowest 5% risk group (L5 CRT-SCORE: -4.42 to -1.60), whereas the highest 5% risk group (H5 CRT-SCORE: 1.44 to 2.89) showed poor survival rates: 78% at 1 year and 22% at 5 years. In conclusion, the CRT-SCORE allows accurate prediction of 1- and 5-year survival rates after CRT using readily available and CRT-specific clinical, electrocardiographic, and echocardiographic parameters. The model may assist clinicians in counseling patients and in decision making.
No takes yet. Share an insight, caveat, or question.
Höke et al. (2017) conducted a cohort in Heart failure with left ventricular ejection fraction ≤35% undergoing cardiac resynchronization therapy (n=1,053). CRT-SCORE was evaluated on 1- and 5-year survival rates / all-cause mortality (AUC 0.773 at 1 year and 0.748 at 5 years). The CRT-SCORE demonstrated good discriminative ability for predicting 1- and 5-year survival after cardiac resynchronization therapy (AUC 0.773 at 1 year and 0.748 at 5 years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: